Back to News
Market Impact: 0.1
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Source: Business Wire
Healthcare & Biotech
Organon said a new pooled post-hoc analysis of Phase 3 data for VTAMA (tapinarof) cream, 1%, will be presented at the 2026 ACAAI Scientific Meeting. The announcement provides no findings or numerical results from the analysis.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
OGN0.20
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates
- Cigna raises annual profit forecast on strength in health services unit
- US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
- Truist raises Zimmer Biomet stock price target on robotics progress